LUNG CANCER

General Cancer

Jyoti D. Patel, MD, recently shared the treatment considerations and decisions she makes when treating patients with non&ndash;small cell lung cancer. Patel, professor of medicine and director of thoracic oncology at the University of Chicago Medicine in Illinois, discussed her treatment considerations for patients with NSCLC based on case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Treatment Regimen for Patients With ALK+ Non-Small Cell Lung Cancer

A 50-Year-Old Woman With ALK-Rearranged NSCLC

H. Jack West, MD, thoracic oncologist at the Swedish Cancer Institute of Swedish Medical Center, discusses the data with atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). West says that the choice of treatment is likely best left to the judgement of the physician and patient.&nbsp;